Galmed Pharmaceuticals Ltd. (GLMD): Net earnings per share for the last 12 months

Galmed Pharmaceuticals (GLMD) TTM earnings per share dynamics correlate with moderate confidence in the brand within the scientific community, with the value stabilizing at -13.71. The business relies on the development of Aramchol to combat fibrosis and NASH; however, the lack of revenue and fierce competition in hepatology create critical risks of failure in the final stages of clinical trials.
Analytical breakdowns for Galmed Pharmaceuticals

Galmed Pharmaceuticals focuses on developing innovative liver disease therapies through its Israeli R&D base. This indicator reflects the final profit distributed per ordinary share over the last twelve months. Investors use this calculation to assess real capital efficiency, excluding issuance noise. A decline in fundamental net income per share TTM signals rising clinical trial costs. The trend in fundamental net income per share TTM determines the financial stability of the business.